Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9826622 | 0.89 | USP2 (0.46) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3370980 | 0.85 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL9111200 | 0.83 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3595211 | 0.77 | USP2 (0.55) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL2077428 | 0.76 | USP2 (0.61) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL1614405 | 0.75 | USP2 (0.58) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4473443 | 0.74 | MMP9 (0.41) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.74 | USP2 (0.75) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14844857 | 0.74 | USP2 (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3369383 | 0.73 | ALDH1A1 (0.50) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-108601788-B | EIF 4A-inhibiting compounds and methods relating thereto | 效应治疗股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3380101-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | USP2 2925/4885TSHR 3587/4885KDM4E 812/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | USP2 2925/4885TSHR 3587/4885KDM4E 812/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | USP2 329/4885TSHR 3099/4885KDM4E 2086/4885 |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | USP2 2925/4885TSHR 3587/4885KDM4E 812/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | USP2 2052/4885TSHR 1451/4885KDM4E 3010/4885 |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | USP2 2925/4885TSHR 3587/4885KDM4E 812/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | USP2 2925/4885TSHR 3587/4885KDM4E 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.